US industry concerned about FDA's data falsification rule
This article was originally published in SRA
The US pharmaceutical and clinical research industry has expressed serious concerns about a new rule proposed by the Food and Drug Administration, which, if finalised, would require sponsors to report to the agency about any individual who has, or may have, engaged in falsification of data in studies involving human or animal subjects1,2.
You may also be interested in...
FDA's Withdrawn Reg On Data Fraud Hangs Over Zolgensma Incident
Democratic senators push data-challenged gene therapy into maw of drug pricing debate as they press acting commissioner Sharpless to bring the hammer down on Novartis, but also question US FDA's decision to withdraw the proposed rule last year.
WHO Consults On Updates To 24-Year-Old GMP Requirements For Pharma Excipients
The World Health Organization wants to update its guideline on manufacturing pharmaceutical excipients to ensure these products meet the requirements for quality and purity that they purport or are represented to possess.
European Commission Steps In To Address Drug Trial Delays Due To IVD Regulation
The commission is in talks with EU member states to identify possible regulatory bottlenecks in the approval of combined clinical trials for a medicinal product and a clinical performance study of an IVD.